Roche Doubles Down on Precision Oncology as FDA Fast-Tracks Tecentriq and EU Approves Companion Test

Roche advances precision oncology with FDA Priority Review for Tecentriq in dMMR/MSI-H colorectal cancer and EU approval of VENTANA MMR RxDx Panel across five cancer types.

Roche is weaving cancer diagnostics and targeted therapy ever tighter with a pair of regulatory advances announced simultaneously. The US Food and Drug Administration has accepted the company’s application for Tecentriq in a specific form of colorectal cancer and granted it Priority Review, while European regulators have broadened the approval for the company’s companion diagnostic test, VENTANA MMR RxDx Panel. The moves underscore a long-term strategy to link diagnosis directly with treatment — a bet that could sharpen Roche’s edge in precision oncology.

The FDA’s Priority Review designation sets a decision deadline of October 2026 and is reserved for therapies that address a significant unmet medical need. Roche’s application is backed by the Phase III ATOMIC trial, which enrolled 712 patients with Stage III colorectal cancer harboring dMMR or MSI-H tumors — a biology present in roughly one in seven colorectal cancer patients. Nearly a third of those with Stage III disease suffer a relapse within five years, underscoring the medical gap. The trial showed that adding Tecentriq to standard FOLFOX6 chemotherapy cut the risk of relapse or death by 50% compared with chemotherapy alone, while the 36-month disease-free survival rate reached 86% in the combination arm versus 76% in the control group. The safety profile matched earlier studies.

Parallel to the US regulatory push, Roche secured EU approval under the In Vitro Diagnostic Regulation for the VENTANA MMR RxDx Panel. The test determines the mismatch repair status of tumors, identifying which patients are likely candidates for checkpoint inhibitors such as Tecentriq as well as drugs from Merck, AstraZeneca and GSK. The new green light covers five cancer types and six indications, expanding the tool’s reach across oncology. Roche is effectively equipping both its own pipeline and competitors’ products with a common diagnostic gateway — a strategy that cements its role as a platform player in immunotherapy.

Investors, however, greeted the double news with a shrug. Roche shares edged up just 0.12% to 324.28 Swiss francs on the SIX Swiss Exchange. The muted reaction reflects the reality that regulatory milestones, while strategically important, do not translate into immediate revenue. Tecentriq is already an established drug, and the eligible patient population for this particular indication is clearly defined, limiting the headline revenue potential.

The true test will come in the months ahead. Roche is also pursuing similar Tecentriq applications with the European Medicines Agency, and the clinical data from ATOMIC further validate its immuno-oncology approach. Meanwhile, the success of the expanded VENTANA panel depends on whether hospitals and clinics adopt it widely in routine practice. When the FDA delivers its verdict next October, it will signal just how far Roche’s integrated diagnostic-therapy model has progressed.